ARCHIVES

In Brief: Hammond Resigned As ACS Officer; Wykoff Slated To Direct FDA Special Populations Office

This article is from The Cancer Letter archive.

Vol. 18 No. 45 | November 20, 1992

Download PDF Visit The Full Archive

Related Articles

VEGF Inhibitor Slows Thyroid Cancer Progression In Some Patients, Study Finds

July 25, 2008

Henschke and Supporters Call For Urgent Action Based On Results Of NLST

May 13, 2011

FASEB: Focus on Research Funding, Not PR

June 14, 2013

Cancer Groups Propose Six Characteristics Of Next FDA Head.

December 19, 2008

FDA Warns of Lymphoma Risk Associated With Breast Implants

January 28, 2011

DCAB Board Okays One Contract Concept, Sends Another Back to Drawing Board

May 22, 1981